Mauna Kea Technologies SAS Cash Flow Conversion Efficiency

Latest as of June 2025: 0.077x

Mauna Kea Technologies SAS cash flow conversion efficiency. Based on the latest financial reports, Mauna Kea Technologies SAS (ALMKT) has a cash flow conversion efficiency ratio of 0.077x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.28 Million ≈ $-2.67 Million USD) by net assets (€-29.42 Million ≈ $-34.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Mauna Kea Technologies SAS (2010–2024)

Cash flow conversion efficiency of Mauna Kea Technologies SAS from 2010 to 2024. This chart illustrates how Mauna Kea Technologies SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALMKT stock price and chart for real-time trading data and today's change.

Mauna Kea Technologies SAS Cash Flow Conversion Ratio Explained

Mauna Kea Technologies SAS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Mauna Kea Technologies SAS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mauna Kea Technologies SAS ranked by their cash flow conversion efficiency. Also see ALMKT stock market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Naas Technology Inc ADR
NASDAQ:NAAS
-0.015x
PLYTEC Holding Berhad
KLSE:0289
0.064x
Ikonisys SA
PA:ALIKO
-0.014x
Nucletron Electronic Aktiengesellschaft
F:NUC
0.004x
EG Corporation
KQ:037370
0.034x
Coal Energy S.A.
WAR:CLE
-0.005x
Duc Long Gia Lai Group JSC
VN:DLG
-0.523x
Cliq Digital AG
XETRA:CLIQ
0.120x

Annual Cash Flow Conversion Efficiency for Mauna Kea Technologies SAS (2010–2024)

The table below shows the annual cash flow conversion efficiency of Mauna Kea Technologies SAS from 2010 to 2024. Review Mauna Kea Technologies SAS (ALMKT) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €-24.39 Million
≈ $-28.51 Million
€-6.32 Million
≈ $-7.39 Million
0.259x +494.90%
2023-12-31 €-17.28 Million
≈ $-20.20 Million
€-753.00K
≈ $-880.34K
0.044x -90.16%
2022-12-31 €-19.93 Million
≈ $-23.29 Million
€-8.83 Million
≈ $-10.32 Million
0.443x -55.43%
2021-12-31 €-10.33 Million
≈ $-12.08 Million
€-10.27 Million
≈ $-12.01 Million
0.994x +50.29%
2020-12-31 €-12.08 Million
≈ $-14.12 Million
€-7.99 Million
≈ $-9.34 Million
0.662x +101.63%
2019-12-31 €253.00K
≈ $295.78K
€-10.27 Million
≈ $-12.01 Million
-40.601x -2872.05%
2018-12-31 €7.98 Million
≈ $9.33 Million
€-10.90 Million
≈ $-12.74 Million
-1.366x -134.80%
2017-12-31 €16.74 Million
≈ $19.58 Million
€-9.74 Million
≈ $-11.39 Million
-0.582x +17.16%
2016-12-31 €11.16 Million
≈ $13.04 Million
€-7.84 Million
≈ $-9.16 Million
-0.702x +15.62%
2015-12-31 €14.09 Million
≈ $16.47 Million
€-11.73 Million
≈ $-13.71 Million
-0.832x -18.67%
2014-12-31 €18.15 Million
≈ $21.22 Million
€-12.73 Million
≈ $-14.88 Million
-0.701x -120.08%
2013-12-31 €30.16 Million
≈ $35.26 Million
€-9.61 Million
≈ $-11.24 Million
-0.319x +3.61%
2012-12-31 €40.16 Million
≈ $46.95 Million
€-13.28 Million
≈ $-15.53 Million
-0.331x -176.02%
2011-12-31 €51.57 Million
≈ $60.30 Million
€-6.18 Million
≈ $-7.22 Million
-0.120x +67.12%
2010-12-31 €6.86 Million
≈ $8.02 Million
€-2.50 Million
≈ $-2.92 Million
-0.364x --

About Mauna Kea Technologies SAS

PA:ALMKT France Medical Devices
Market Cap
$21.29 Million
€18.21 Million EUR
Market Cap Rank
#24757 Global
#397 in France
Share Price
€0.09
Change (1 day)
-2.27%
52-Week Range
€0.07 - €0.22
All Time High
€5.37
About

Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate… Read more